down arrow

Ampio Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03209T3077
USD
0.01
0.00 (0.00%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.010.01

52 Week

0.000.16
Valuation
Technical
Day's Volume

CASH

695

Shareholding (Dec 2023)

FII

0.32%

Held by 16 FIIs

DII

89.52%

Held by 10 DIIs

Promoter

0.00%

How big is Ampio Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Ampio Pharmaceuticals, Inc. has a market capitalization of 0.00, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -8.63 million over the latest four quarters. Shareholder's funds are 3.36 million, and total assets are 5.74 million.

As of Jun 18, Ampio Pharmaceuticals, Inc. has a market capitalization of 0.00, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.00 million, while the sum of net profit for the same period is -8.63 million.<BR><BR>As of Dec 23, the shareholder's funds amount to 3.36 million, and the total assets are reported at 5.74 million.

Read More

What does Ampio Pharmaceuticals, Inc. do?

22-Jun-2025

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for inflammatory conditions. As of December 2023, it has a market cap of $0 million and reported a net profit loss of $2 million.

Overview: <BR>Ampio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for prevalent inflammatory conditions within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -2 Million (Quarterly Results - Dec 2023) <BR>Market cap: USD 0.00 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.14 <BR>Return on Equity: -265.51% <BR>Price to Book: 0.00<BR><BR>Contact Details: <BR>Address: 373 Inverness Pkwy Ste 200, ENGLEWOOD CO: 80112-5898 <BR>Tel: 1 720 4376500 <BR>Website: http://ampiopharma.com/

Read More

Who are in the management team of Ampio Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Ampio Pharmaceuticals, Inc. includes Mr. Michael Macaluso as Chairman and CEO, with Dr. David Bar-Or as a Director and Mr. Philip Coelho, Mr. Richard Giles, and Dr. David Stevens serving as Independent Directors.

As of March 2022, the management team of Ampio Pharmaceuticals, Inc. includes Mr. Michael Macaluso, who serves as the Chairman of the Board and Chief Executive Officer. Other members of the board include Dr. David Bar-Or as a Director, and Mr. Philip Coelho, Mr. Richard Giles, and Dr. David Stevens, all serving as Independent Directors.

Read More

Is Ampio Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of August 2, 2016, Ampio Pharmaceuticals, Inc. is considered overvalued and does not qualify for a favorable valuation grade due to poor financial metrics, including a P/E ratio of -0.0003 and a one-year return of -97.92%, significantly underperforming against the S&P 500.

As of 2 August 2016, the valuation grade for Ampio Pharmaceuticals, Inc. moved from risky to does not qualify. The company is currently considered overvalued given its financial metrics and performance. The price-to-book value stands at a mere 0.04, while the EV to EBITDA ratio is 0.40, indicating significant underperformance relative to its peers. Additionally, the return on capital employed (ROCE) is extraordinarily high at 951.80%, but this is misleading due to the negative return on equity (ROE) of -265.51%.<BR><BR>In comparison to its peers, Ampio Pharmaceuticals, Inc. does not qualify with a P/E ratio of -0.0003, while Kinnate Biopharma, Inc. is rated fair with a P/E of -1.1313, and ADC Therapeutics SA is rated risky with a P/E of -2.1005. The stark contrast in valuation and performance metrics suggests that Ampio is not positioned favorably in the market. Furthermore, the company's stock has dramatically underperformed against the S&P 500, with a one-year return of -97.92% compared to the index's 10.26%, reinforcing the notion of overvaluation.

Read More

Is Ampio Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of August 26, 2025, Ampio Pharmaceuticals, Inc. is in a mildly bearish trend due to negative RSI indicators and underperformance compared to the S&P 500, despite a mildly bullish weekly MACD.

As of 26 August 2025, the technical trend for Ampio Pharmaceuticals, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by a bearish RSI on both weekly and monthly time frames, along with a mildly bearish daily moving average. The weekly MACD remains mildly bullish, but the overall indicators suggest weakness. The company has a year-to-date return of 3.85%, underperforming the S&P 500's 12.22%, and has significantly negative returns over the longer term, indicating a challenging environment.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.14

stock-summary
Return on Equity

-265.51%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
(Quarterly Results - Dec 2023)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
92.59%
0%
92.59%
6 Months
73.33%
0%
73.33%
1 Year
100.0%
0%
100.0%
2 Years
-99.84%
0%
-99.84%
3 Years
-99.92%
0%
-99.92%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

Ampio Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Ampio Pharmaceuticals, Inc. technically bullish or bearish?

As of 26 August 2025, the technical trend for Ampio Pharmaceuticals, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by a bearish RSI on both weekly and monthly time frames, along with a mildly bearish daily moving average. The weekly MACD remains mildly bullish, but the overall indicators suggest weakness. The company has a year-to-date return of 3.85%, underperforming the S&P 500's 12.22%, and has significantly negative returns over the longer term, indicating a challenging environment....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
2.79%
EBIT to Interest (avg)
-17.07
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.14
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
23.61%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.04
EV to EBIT
0.39
EV to EBITDA
0.40
EV to Capital Employed
3.67
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
951.80%
ROE (Latest)
-265.51%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bullish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 19 Schemes (10.16%)

Foreign Institutions

Held by 16 Foreign Institutions (0.32%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'23 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2023 is 0.00% vs 0.00% in Dec 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2023 is 4.55% vs 64.52% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.20",
          "val2": "-2.30",
          "chgp": "4.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.10",
          "val2": "-2.20",
          "chgp": "4.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 47.24% vs 4.68% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.30",
          "val2": "-18.30",
          "chgp": "49.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "3.80",
          "chgp": "-92.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.60",
          "val2": "-16.30",
          "chgp": "47.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'23 - YoYstock-summary
Dec'23
Dec'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.20
-2.30
4.35%
Interest
0.00
0.00
Exceptional Items
0.00
0.40
-100.00%
Consolidate Net Profit
-2.10
-2.20
4.55%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Dec 2023 is 0.00% vs 0.00% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2023 is 4.55% vs 64.52% in Dec 2022

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-9.30
-18.30
49.18%
Interest
0.00
0.00
Exceptional Items
0.30
3.80
-92.11%
Consolidate Net Profit
-8.60
-16.30
47.24%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 47.24% vs 4.68% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Ampio Pharmaceuticals, Inc. stock-summary
stock-summary
Ampio Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.
Company Coordinates stock-summary
Company Details
373 Inverness Pkwy Ste 200 , ENGLEWOOD CO : 80112-5898
stock-summary
Tel: 1 720 4376500
stock-summary
http://ampiopharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."